Sanofi’s top-line performance for Q4 was weaker than expected, but profitability made up for the under-performance, along with a slightly better-than-expected outlook for 2019. Sales grew by 3.9% at CER and at 2.6% at CER/CS to €9bn, with the pharma business growing by 3% (CER/CS), consumer healthcare by 2%, and vaccine by 9.7%. Geographically, Europe (-4.8%) was a major disappointment, primarily due to generic erosion of the mature established drugs and a weak consumer health busi
12 Feb 2019
Strong outlook for 2019 but signals still mixed
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong outlook for 2019 but signals still mixed
Sanofi’s top-line performance for Q4 was weaker than expected, but profitability made up for the under-performance, along with a slightly better-than-expected outlook for 2019. Sales grew by 3.9% at CER and at 2.6% at CER/CS to €9bn, with the pharma business growing by 3% (CER/CS), consumer healthcare by 2%, and vaccine by 9.7%. Geographically, Europe (-4.8%) was a major disappointment, primarily due to generic erosion of the mature established drugs and a weak consumer health busi